Get access

Cost of care for early- and late-stage oral and pharyngeal cancer in the California Medicaid population

Authors

  • Joshua D. Epstein MA,

    1. Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, California
    Search for more papers by this author
    • J.D. Epstein, T.K. Knight and M.B. Nichol have reported a financial interest/relationship with Zila Inc as the recipients of an unrestricted research grant. J.B. Epstein has reported a financial interest/relationship with Zila Inc as a member of the Medical Advisory Board. M.A. Bride has reported a financial interest/relationship with Zila Inc as the Director of Medical Affairs.

  • Tara K. Knight PhD,

    1. Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, California
    Search for more papers by this author
    • J.D. Epstein, T.K. Knight and M.B. Nichol have reported a financial interest/relationship with Zila Inc as the recipients of an unrestricted research grant. J.B. Epstein has reported a financial interest/relationship with Zila Inc as a member of the Medical Advisory Board. M.A. Bride has reported a financial interest/relationship with Zila Inc as the Director of Medical Affairs.

  • Joel B. Epstein DMD, MSD, FRCD(c),

    1. Department of Oral Medicine and Diagnostic Sciences, College of Dentistry and Cancer Center, College of Medicine, University of Illinois, Chicago, Illinois
    Search for more papers by this author
    • J.D. Epstein, T.K. Knight and M.B. Nichol have reported a financial interest/relationship with Zila Inc as the recipients of an unrestricted research grant. J.B. Epstein has reported a financial interest/relationship with Zila Inc as a member of the Medical Advisory Board. M.A. Bride has reported a financial interest/relationship with Zila Inc as the Director of Medical Affairs.

  • Mark A. Bride DDS,

    1. Zila, Inc, Phoenix, Arizona
    Search for more papers by this author
  • Michael B. Nichol PhD

    Corresponding author
    1. Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, California
    • Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, California
    Search for more papers by this author
    • J.D. Epstein, T.K. Knight and M.B. Nichol have reported a financial interest/relationship with Zila Inc as the recipients of an unrestricted research grant. J.B. Epstein has reported a financial interest/relationship with Zila Inc as a member of the Medical Advisory Board. M.A. Bride has reported a financial interest/relationship with Zila Inc as the Director of Medical Affairs.


  • Part of this study was presented at the International Society for Pharmacoeconomics and Outcomes Research's 11th Annual International Meeting in Philadelphia, PA, on May 21, 2006.

Abstract

Background.

This study documents the direct medical costs associated with treating oral and pharyngeal squamous cell carcinoma (OSCC) as early- or late-stage disease according to the current standard of care.

Methods.

This retrospective analysis of California Medicaid claims data calculated direct payments for patients diagnosed with OSCC. Patients were defined as being treated for early- or late-stage disease based on treatment modality. Regression determined significant predictors of year-1 cost of care following diagnosis.

Results.

Median year-1 cost of care following initial diagnosis was $25,319 for the 229 patients identified. Regression results determined that treatment modality and medical comorbidities were significant in predicting costs (p < .05). Costs for patients treated as having early-stage OSCC were approximately 36% less than for those treated as having late-stage disease (p = .002).

Conclusion.

Treatment for OSCC is a significant cost from Medicaid's perspective, and these data suggest early detection may ease its economic burden. © 2007 Wiley Periodicals, Inc. Head Neck, 2008

Ancillary